Julissa Viana News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose.

Melissa forstJulissa vianaKatarina luptakovaCorporate communicationsGenentech united states incEuropean society for medical oncologyExchange commissionRoche groupClinical developmentOncology congress onOncology congressXilio therapeutics incEuropean societyMedical oncologyImmuno oncology congressOngoing phase

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses and 31% disease control rate across all dose levels in a range of solid tumor types, including.

United statesSan diegoKatarina luptakovaJulissa vianaHoward kaufmanMelissa forstClinical developmentCorporate communicationsExchange commissionLinkedin xilio therapeutics incXilio therapeutics incSociety for immunotherapy of cancerAnnual meetingMassachusetts general hospitalOngoing phasePreliminary anti tumor

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

WALTHAM, Mass., Oct. 31, 2023 Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with.

United statesSan diegoHoward kaufmanMelissa forstJulissa vianaExchange commissionSociety for immunotherapy of cancerLinkedin xilio therapeutics incXilio therapeutics incCorporate communicationsAnnual meetingXilio therapeuticsRegarding forward lookingPrivate securities litigation reform actQuarterly reportMedia inquiries

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesMelissa forstJulissa vianaLinkedin xilio therapeutics incCorporate communicationsXilio therapeutics incSociety for immunotherapy of cancerExchange commissionXilio therapeuticsAnnual meetingHuman studyAdvanced solid tumorsExhibit hallsTumor activatedHalf life extended

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting - Xilio Therapeutics (NASDAQ:XLO)

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living

United statesSan diegoMelissa forstJulissa vianaLinkedin xilio therapeutics incExchange commissionSociety for immunotherapy of cancerCorporate communicationsXilio therapeutics incAnnual meetingHuman studyAdvanced solid tumorsExhibit hallsTumor activatedHalf life extendedPromoted potent anti tumor immunity